Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04665323 · ClinicalTrials.gov registry record
An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.
A clinical trial, sponsored by Ipsen.
- Completed
- Registry status
- 411
- Enrollment target
NCT04665323: Completed study, sponsored by Ipsen.
NCT04665323 is a clinical trial that has completed, run by Ipsen. The registered enrollment target is 411 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04665323 has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- 411 participants
- Enrollment target
Study Summary
The FOP burden of illness (BoI) survey aims to assess the impact of the burden of FOP on patients and their families. The study is being conducted online and available for residents in Argentina, Brazil, Canada, France, Germany, Italy, Japan, Mexico, Poland, Russia, South Korea, Spain, Sweden, the US, and the UK.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 411 participants |
| Start Date | 2021-01-18 |
| Est. Completion | 2021-04-30 |
What the finished NCT04665323 record still lists
NCT04665323 is an observational study that tracks outcomes without assigning an intervention. The registered 411 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04665323 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04665323 about?
NCT04665323 is a clinical study titled "An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.". The FOP burden of illness (BoI) survey aims to assess the impact of the burden of FOP on patients and their families. The study is being conducted online and available for residents in Argentina, Brazil, Canada, France, Germany, Italy, Japan, Mexico, Poland, Russia, South Korea, Spain, Sweden, the U...
What is the current status of trial NCT04665323?
This trial is currently completed. The enrollment target is 411 participants. The study started on 2021-01-18. Estimated completion is 2021-04-30.
Who is sponsoring clinical trial NCT04665323?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
- NCT06699212 · 412 participants · Phase 3
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI